ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ

Inclusion Criteria: Male and female participants who are healthy Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, dermatological, or allergic disease * Any condition possibly affecting drug absorption * Known immunodeficiency. * Infection with hepatitis B or hepatitis C viruses * acute or chronic infections or infection history judged to be clinically significant by the investigator * History of any lymphoproliferative disorder * known present or a history of malignancy other than a successfully treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ. * live (attenuated) vaccines within 6 weeks prior to the first dose of investigational product.